profit from every €100 of sales.
€0€100
Faes Farma
€4.99-0.30% today
-2.1% since Dec 22, 25
1-year low €4.341-year high €5.38
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €19.50 for every €1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Faes Farma sold, what it kept, and what it did with the cash.
Sales went from €439 million in 2022 to €610 million in 2025, with €79.6 million of profit last year.
SalesProfit
Faes Farma handed back more cash to shareholders than it generated last year.
€56M
Free cash flow 2025€55M
Bought back its own shares–
Paid as dividends€56M
Cash vs. debt€117M vs. €400M
Faes Farma vs. similar companies
Faes Farma grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Faes Farma | 19.5× · Fair price | ||
 Merck KGaA | 24.8× · Fair price | ||
 Takeda Pharmaceutical | 101.0× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.1× · Expensive |
AI analysis
An AI analyst reads Faes Farma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 439 | 451 | 494 | 610 | |
| 282 | 297 | 327 | 396 | |
| 102 | 104 | 109 | 89 | |
| 121 | 123 | 128 | 120 | |
| 89 | 92 | 111 | 80 | |
| 0.29 | 0.30 | 0.36 | 0.25 | |
| 64.3% | 65.9% | 66.1% | 64.9% | |
| 23.3% | 23.0% | 22.0% | 14.6% | |
| 20.4% | 20.4% | 22.6% | 13.0% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 727 | 777 | 853 | 1,342 |
| Cash | 66 | 35 | 64 | 117 |
| Total debt | 33 | 24 | 2 | 400 |
| Total liabilities | 125 | 113 | 126 | 596 |
| 601 | 662 | 726 | 745 | |
| 306 | 311 | 309 | 319 | |
| 12.0% | 11.3% | 11.1% | 6.0% | |
| 14.9% | 13.9% | 15.3% | 10.7% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 107 | 101 | 115 | 78 | |
| 81 | 102 | 40 | 24 | |
| 26 | -1 | 76 | 55 | |
| Dividends paid | 18 | 15 | 48 | 56 |
| 0 | 18 | 0 | – | |
| 0 | 1 | 1 | – |
Valuation
- 19.8×
- –
- –
- 1.9×
- 2.6×
- 28.7×
- 15.5×
- 3.5%
- 5.1%
- 3.5%
Profitability
- 64.9%
- 14.6%
- 13.0%
- –
- 6.0%
- 10.1%
- –
- –
- –
- –
Growth
- +11.6%
- −5.2%
- –
- –
- +1.4%
Financial health
- 2.4×
- 0.54
- –
- 15.8×
- 2.61
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 46%of 946
Top 36%of 872
Top 30%of 564
Top 49%of 867
Top 31%of 986
3.5%of the share price, paid each year
On $1,000 invested$35a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
70.0% of its profit
Room to growStretchedMore than it earns: 101.6%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
54No pass
Benjamin Graham
69Pass
Philip Fisher
51No pass
Peter Lynch
34No pass
Joel Greenblatt
23No pass
Charlie Munger
43No pass
Terry Smith
37No pass
Questions about Faes Farma
Is Faes Farma a good stock to buy?
A solid business at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Faes Farma AI analysis
What does Faes Farma do?
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. It is in Drug Manufacturers - Specialty & Generic, based in Leioa, Spain, with 2,677 employees.
Does Faes Farma pay a dividend?
Yes. At today's price the dividend is 3.6% a year, about 70% of its yearly profit. In 2025 it paid out €55.7 million in dividends.
Is Faes Farma stock halal?
Yes. Faes Farma passes our halal screen: its business is permitted and its debt is 26% of its market value, under the 30% limit. How we check
Who are Faes Farma's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Faes Farma's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.